Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Analysts at Cantor Fitzgerald issued their FY2020 earnings per share (EPS) estimates for Amicus Therapeutics in a research report issued to clients and investors on Thursday, October 17th. Cantor Fitzgerald analyst E. Merle forecasts that the biopharmaceutical company will post earnings of ($0.82) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.34) EPS for the quarter, hitting analysts’ consensus estimates of ($0.34). The business had revenue of $44.13 million during the quarter, compared to analysts’ expectations of $41.14 million. Amicus Therapeutics had a negative net margin of 336.41% and a negative return on equity of 66.79%. The business’s quarterly revenue was up 107.1% on a year-over-year basis. During the same period last year, the company posted ($0.33) earnings per share.
NASDAQ:FOLD opened at $8.13 on Monday. The company has a current ratio of 7.09, a quick ratio of 6.97 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -6.11 and a beta of 1.57. The firm has a fifty day simple moving average of $8.85 and a two-hundred day simple moving average of $11.41. Amicus Therapeutics has a 12 month low of $7.11 and a 12 month high of $14.61.
Institutional investors have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd bought a new position in shares of Amicus Therapeutics during the second quarter valued at about $49,000. US Bancorp DE lifted its position in shares of Amicus Therapeutics by 50.9% during the second quarter. US Bancorp DE now owns 4,896 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,651 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Amicus Therapeutics during the second quarter valued at about $73,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in shares of Amicus Therapeutics during the second quarter valued at about $122,000. Finally, Weil Company Inc. bought a new position in shares of Amicus Therapeutics during the second quarter valued at about $125,000.
In other Amicus Therapeutics news, CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $10.05, for a total value of $201,000.00. Following the transaction, the chief executive officer now directly owns 770,194 shares of the company’s stock, valued at $7,740,449.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Burke W. Whitman acquired 4,945 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was acquired at an average cost of $10.07 per share, for a total transaction of $49,796.15. Following the completion of the purchase, the director now directly owns 21,612 shares of the company’s stock, valued at approximately $217,632.84. The disclosure for this purchase can be found here. Insiders sold 54,500 shares of company stock worth $567,945 over the last ninety days. Insiders own 2.50% of the company’s stock.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Featured Story: How to invest in a bear market
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.